SAN DIEGO--(BUSINESS WIRE)--ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that Allergan, Inc. will initiate an exploratory clinical study with a small molecule drug candidate for the treatment of glaucoma, which triggered a milestone payment to ACADIA. The selective muscarinic compound emanates from a discovery made at ACADIA and is being developed pursuant to the companies’ collaboration focused on novel treatments for glaucoma.
